RNS Number : 6097Q
Oxford Biomedica PLC
01 March 2016
 

 

For filings with the FCA include the annex


For filings with issuer exclude the annex



TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi



1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached: ii

Oxford Biomedica Plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

x

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached


An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments


An event changing the breakdown of voting rights


Other (please specify):

 



3. Full name of person(s) subject to the
notification obligation: iii

Prudential plc group of companies

4. Full name of shareholder(s)
 (if different from 3.):iv

 

Prudential plc

M&G Group Limited

M&G Limited

M&G Investment Management Limited

M&G Securities Limited

 

5. Date of the transaction and date on
which the threshold is crossed or
reached: v

25 February 2016

6. Date on which issuer notified:

29 February 2016

7. Threshold(s) that is/are crossed or
reached: vi, vii

17% -18%


 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of
shares


if possible using
the ISIN CODE

Situation previous
to the triggering
transaction

Resulting situation after the triggering transaction

Number
of
Shares

Number
of
Voting
Rights

Number
of shares

Number of voting
rights

% of  voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

 

ORD GBP0.01

GB0006648157

460,648,423

460,648,423

490,443,106

0

490,443,106

0

18.14%


B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial
instrument

Expiration
date xiii

Exercise/
Conversion Period xiv

Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.

% of voting
rights







C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial
instrument

Exercise price

Expiration date xvii

Exercise/
Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 





 

 

Nominal

Delta




Total (A+B+C)

Number of voting rights

Percentage of voting rights

490,443,106

18.14%

 

 

 

9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable: xxi

 

Prudential plc (parent Company) - 490,443,106 (18.14%)

M&G Group Limited (wholly owned subsidiary of Prudential plc) - 490,443,106 (18.14%)

M&G Limited (wholly owned subsidiary of M&G Group Limited) - 490,443,106 (18.14%)

M&G Investment Management Limited (wholly owned subsidiary of M&G Limited) - 490,443,106 (18.14%)

M&G Securities Limited (wholly owned subsidiary of M&G Limited) - 466,658,885 (17.26%)

 


Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will cease to hold:

N/A

12. Date on which proxy holder will cease to hold voting rights:

N/A



13. Additional information:

 

 

14. Contact name:

Tim Watts

15. Contact telephone number:

Chief Financial Officer, Oxford BioMedica

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUASKRNVAORRR